Neuropsychobiology

Pharmacopsychiatry

Oxiracetam in the Treatment of Primary Degenerative and Multi-Infarct Dementia: A Double-Blind, Placebo-Controlled Study

Maina G.a · Fiori L.a · Torta R.a · Fagiani M.B.a · Ravizza L.a · Bonavita E.b · Ghiazza B.c · Teruzzi F.c · Zagnoni P.G.d · Ferrario E.e · Belloni G.f · Tass G.f · Inzoli M.R.g · Lombardi G.g · Voltolini G.B.h · Gherardi G.h · Martinazzoli A.i · Straneo U.i · Bernini P.A.j · Mazzocchi P.j · Belloni G.k · Soldati M.k · Stramba-Badiale M.l · Castoldi C.l · Rossi F.A.m · Balladore G.E.m · Macciolli D.M.n

Author affiliations

aClinica Psichiatrica, Università di Torino, Italia; bDivisione di Geriatria, Ospedale Civile, lmola, Italia; cDivisione di Geriatria I, Ospedale San Gerardo, Monza, Italia; dDivisione di Neurologia, Ospedale Santa Croce, Cuneo, Italia; eUnità Operativa di Medicina Generale, USL 25, Piombino, Italia; fClinica Zucchi, Carate Brianza, Italia; gDivisione di Medicina Psichiatrica, Ospedale Sant’Orsola, Brescia, Italia; hIst Neurogeriatrico ‘V. Marchi’, Reggio Emilia, Italia; iOspedale Civile, Breno, Italia; jOspedale Civile, Varzi, Italia; kPoliclinico San Matteo, Presidio di Belgioioso, Pavia, Italia; lIst Geriatrico Golgi, Abbiategrasso, Italia; mDivisione di Medicina Interna, Ospedale Civile Sampierdarena, Genova, Italia; nIst per Lungodegenti ‘E. Brignole’ Genova, Italia

Related Articles for ""

Neuropsychobiology 1989;21:141–145

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Pharmacopsychiatry

Published online: February 20, 2008
Issue release date: 1989

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800-mg tablets), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed forms of dementia. Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 4, 8 and 12 weeks of treatment, and by the Blessed Dementia Scale and the Newcastle Memory, Information and Concentration Scale (NMICS), administered at the beginning and at the end of the study. Three hundred and seven patients were enrolled, 18 of whom were excluded from the analysis because of violation of the protocol. Two hundred and eighty-nine patients were analyzed (145 m, 144 f, mean age 73 years) and 272 completed the study; 3 patients in each treatment group were withdrawn because of poor tolerability, 10 because of poor compliance and 1 patient because of the occurrence of a cerebral stroke. A significantly (p < 0.01) different effect, in favor of oxiracetam, was observed in the three main efficacy criteria (i.e. IPSC-E, Blessed Dementia Scale and NMIC total scores), and confirmed by descriptive analyses carried out on some subitems of the scales used. Thirty-one patients on oxiracetam and 27 on placebo complained of a total of 35 and 32 minor unwanted effects, respectively. No clinically or statistically significant changes were observed on routine laboratory examinations.

© 1989 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Pharmacopsychiatry

Published online: February 20, 2008
Issue release date: 1989

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP